Offering expert, practical guidance through the decision-making process,Differential Diagnoses in Surgical Pathology: Gynecologic Tract, Second Edition, by Drs. Russell Vang, Anna Yemelyanova, and Jeffrey D. Seidman, helps you systematically solve tough diagnostic challenges in gynecologic pathology and arrive at a correct diagnosis between commonly confused entities. In this fully revised edition, lesions are presented side by side for easy comparison, with clinical and pathological findings in short outline format followed by several full-color images. In addition to illustrating and discussing the classical features of these entities, the authors emphasize atypical features that can complicate diagnoses.
1. Cover - p. Cover 2. Title Page - p. i 3. Copyright - p. iv 4. Preface - p. v 5. Acknowledgments - p. vii 6. Contents - p. ix 7. CHAPTER 1 VULVA AND VAGINA - p. 1 8. 1.1 Vestibular papillomatosis (hymenal tag) vs Condyloma acuminatum - p. 2 9. 1.2 Condyloma acuminatum vs Squamous papilloma - p. 5 10. 1.3 Condyloma acuminatum vs Seborrheic keratosis - p. 8 11. 1.4 Condyloma acuminatum vs Verruca vulgaris (common wart) - p. 11 12. 1.5 Verrucous carcinoma vs Condyloma acuminatum - p. 13 13. 1.6 High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) with condylomatous features vs Condyloma acuminatum - p. 16 14. 1.7 High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) vs Benign squamous epithelium (vulvar skin) - p. 19 15. 1.8 Differentiated-type vulvar intraepithelial neoplasia vs Reactive/reparative atypia - p. 22 16. 1.9 High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) vs Differentiated-type vulvar intraepithelial neoplasia - p. 25 17. 1.10 Basal cell carcinoma vs Basaloid squamous cell carcinoma - p. 28 18. 1.11 Invasive squamous cell carcinoma vs High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) with extension into skin adnexal structures - p. 31 19. 1.12 Invasive squamous cell carcinoma vs High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) with convoluted architecture and/or tangential orientation - p. 34 20. 1.13 Primary extramammary Paget disease vs Pagetoid high-grade squamous intraepithelial lesion (pagetoid HSIL, VIN 2-3) - p. 37 21. 1.14 Melanoma in situ vs Primary extramammary Paget disease - p. 40 22. 1.15 Ectopic prostatic tissue vs Primary vaginal adenocarcinoma - p. 43 23. 1.16 Metastatic adenocarcinoma vs Primary vaginal adenocarcinoma - p. 45 24. 1.17 Prolapsed fallopian tube vs Vaginal adenocarcinoma - p. 48 25. 1.18 Bartholin gland hyperplasia/adenoma vs Primary mucinous carcinoma (Bartholin gland carcinoma) - p. 51 26. 1.19 Hidradenoma papilliferum (papillary hidradenoma) vs Vulvar adenocarcinoma arising from mammary-like glands - p. 53 27. 1.20 Fibroepithelial (mesodermal) stromal polyp vs Aggressive angiomyxoma - p. 56 28. 1.21 Vulvar lymphedema vs Aggressive angiomyxoma - p. 58 29. 1.22 Aggressive angiomyxoma vs Angiomyofibroblastoma - p. 60 30. 1.23 Cellular angiofibroma vs Leiomyoma - p. 62 31. 1.24 Myofibroblastoma vs Leiomyoma - p. 65 32. 1.25 Neurofibroma vs Myofibroblastoma - p. 68 33. 1.26 Spindle cell melanoma vs Leiomyosarcoma - p. 71 34. 1.27 Kaposi sarcoma vs Sarcomatoid (spindled) squamous cell carcinoma - p. 74 35. CHAPTER 2 CERVIX - p. 81 36. 2.1 Low-grade squamous intraepithelial lesion (LSIL) vs Nondiagnostic squamous atypia - p. 82 37. 2.2 Low-grade squamous intraepithelial lesion (LSIL) vs High-grade squamous intraepithelial lesion (HSIL) - p. 85 38. 2.3 Papillary immature squamous metaplasia (immature condyloma) vs Papillary squamous cell carcinoma - p. 88 39. 2.4 High-grade squamous intraepithelial lesion (HSIL) vs Immature squamous metaplasia - p. 91 40. 2.5 High-grade squamous intraepithelial lesion (HSIL) vs Transitional cell metaplasia/atrophy - p. 94 41. 2.6 Attenuated high-grade squamous intraepithelial lesion (HSIL) vs Atypical immature squamous metaplasia - p. 97 42. 2.7 High-grade squamous intraepithelial lesion (HSIL) with extension into endocervical glands vs Superficially invasive squamous cell carcinoma - p. 100 43. 2.8 Adenoid basal epithelioma vs High-grade squamous intraepithelial lesion (HSIL) with extension into endocervical glands - p. 103 44. 2.9 High-grade squamous intraepithelial lesion (HSIL) vs Stratified mucin-producing intraepithelial lesion (SMILE) - p. 106 45. 2.10 Stratified mucin-producing intraepithelial lesion (SMILE) vs Squamous metaplasia with overlying mucinous epithelium - p. 109 46. 2.11 Intraepithelial spread of bladder urothelial carcinoma into the cervix vs High-grade squamous intraepithelial lesion (HSIL) - p. 112 47. 2.12 HPV-related endocervical adenocarcinoma in situ vs Tuboendometrioid metaplasia - p. 115 48. 2.13 Florid adenocarcinoma in situ (AIS, HPV-related) vs HPV-related invasive well-differentiated adenocarcinoma of usual type with AIS-like pattern/Silva pattern A - p. 118 49. 2.14 HPV-related endocervical adenocarcinoma vs Microglandular hyperplasia - p. 121 50. 2.15 HPV-independent endocervical adenocarcinoma (including minimal deviation adenocarcinoma/gastric-type adenocarcinoma) vs Lobular endocervical glandular hyperplasia (LEGH) - p. 124 51. 2.16 HPV-independent endocervical adenocarcinoma (including minimal deviation adenocarcinoma/gastric-type adenocarcinoma) vs HPV-related endocervical adenocarcinoma, mucinous type - p. 127 52. 2.17 Secondary cervical involvement by endometrial carcinoma: cervical stromal invasion vs Confinement to endocervical mucosa - p. 130 53. 2.18 HPV-related invasive endocervical adenocarcinoma of usual type vs Secondary cervical involvement by endometrial endometrioid carcinoma, FIGO grade 1 - p. 132 54. 2.19 Mesonephric hyperplasia (hyperplastic mesonephric duct remnants) vs Secondary involvement of the cervix by endometrial endometrioid adenocarcinoma - p. 135 55. 2.20 Mesonephric hyperplasia (hyperplastic mesonephric duct remnants) vs HPV-related invasive endocervical adenocarcinoma of usual type - p. 138 56. 2.21 Secondary cervical involvement by endometrial endometrioid carcinoma, FIGO grade 3 vs Poorly differentiated cervical squamous cell carcinoma or adenosquamous carcinoma - p. 141 57. 2.22 Placental site nodule/plaque vs Squamous cell carcinoma (well-differentiated, keratinizing) - p. 144 58. 2.23 Squamous cell carcinoma vs Neuroendocrine carcinoma - p. 147 59. 2.24 Embryonal rhabdomyosarcoma, botryoid type vs Inflamed benign endocervical polyp - p. 151 60. 2.25 NTRK-rearranged spindle cell neoplasm/sarcoma vs Inflammatory myofibroblastic tumor - p. 154 61. CHAPTER 3 UTERINE CORPUS (EPITHELIAL LESIONS) - p. 163 62. 3.1 Menstrual endometrium vs Anovulation-related endometrial stromal breakdown/dysfunctional uterine bleeding - p. 164 63. 3.2 Artifactual glandular crowding vs Endometrial hyperplasia - p. 167 64. 3.3 Complex atypical hyperplasia vs Complex hyperplasia without atypia (+/− metaplastic changes) - p. 170 65. 3.4 Endometrial hyperplasia/carcinoma with secretory differentiation vs Secretory endometrium - p. 173 66. 3.5 Endometrial hyperplasia/carcinoma with progestin treatment effect vs Secretory/gestational endometrium - p. 176 67. 3.6 Complex atypical hyperplasia vs FIGO grade 1 endometrioid carcinoma - p. 179 68. 3.7 Fragments of FIGO grade 1 endometrioid carcinoma with metaplastic-like differentiation vs Benign endometrial tissue with metaplastic changes in biopsy/curettage specimens - p. 181 69. 3.8 FIGO grade 1 endometrioid carcinoma with prominent squamous differentiation vs FIGO grade 2 endometrioid carcinoma - p. 184 70. 3.9 Endometrioid carcinoma with papillary architecture vs Serous carcinoma - p. 187 71. 3.10 Endometrioid carcinoma with small nonvillous papillae vs Serous carcinoma - p. 190 72. 3.11 Endometrioid carcinoma vs Serous carcinoma with glandular architecture - p. 193 73. 3.12 Serous intraepithelial carcinoma vs Benign endometrial tissue with reactive/degenerative atypia - p. 197 74. 3.13 High-grade neuroendocrine carcinoma vs Endometrioid carcinoma, FIGO grade 3 - p. 200 75. 3.14 Endometrioid carcinoma with clear cells vs Clear cell carcinoma - p. 203 76. 3.15 Arias-Stella reaction vs Clear cell carcinoma - p. 206 77. 3.16 Corded and hyalinized pattern of endometrioid carcinoma vs Malignant mixed müllerian tumor (MMMT; carcinosarcoma) - p. 209 78. 3.17 High-grade endometrial carcinoma (FIGO grade 3 endometrioid carcinoma/serous carcinoma) vs Malignant mixed müllerian tumor (MMMT; carcinosarcoma) - p. 213 79. 3.18 Dedifferentiated carcinoma vs High-grade endometrial carcinoma (malignant mixed müllerian tumor [MMMT; carcinosarcoma]/FIGO grade 3 endometrioid carcinoma) - p. 216 80. 3.19 Mesonephric/mesonephric-like adenocarcinoma vs Endometrioid carcinoma - p. 220 81. 3.20 Endometrial carcinoma involving irregular endometrial-myometrial junction vs Endometrial carcinoma with superficial myoinvasion - p. 223 82. 3.21 Endometrial carcinoma with involvement of adenomyosis vs Endometrial carcinoma with myoinvasion - p. 226 83. 3.22 Endometrial carcinoma with vascular pseudoinvasion vs Endometrial carcinoma with true lymph-vascular space invasion (LVSI) - p. 229 84. 3.23 Minute and detached fragments of ovarian/tubal high-grade serous carcinoma in uterine biopsy/curettage vs Primary endometrial serous carcinoma - p. 233 85. 3.24 Metastatic nongynecologic carcinoma with glandular pattern involving endometrium vs Endometrial endometrioid carcinoma - p. 236 86. 3.25 Secondary uterine corpus involvement by cervical poorly differentiated squamous cell carcinoma vs Primary endometrial FIGO grade 3 endometrioid carcinoma - p. 239 87. 3.26 Endometrial biopsy/curettage: secondary endometrial involvement by endocervical well-differentiated adenocarcinoma of usual type vs Primary endometrial FIGO grade 1 endometrioid carcinoma - p. 242 88. 3.27 Endocervical microglandular hyperplasia (MGH) vs Microglandular hyperplasia (MGH)-like endometrial carcinoma in biopsy/curettage specimens - p. 246 89. CHAPTER 4 UTERINE CORPUS (PURE MESENCHYMAL AND MIXED EPITHELIAL-MESENCHYMAL LESIONS) - p. 255 90. 4.1 Atypical leiomyoma vs Leiomyosarcoma - p. 256 91. 4.2 Infarcted cellular leiomyoma vs Smooth muscle tumor of uncertain malignant potential (STUMP) - p. 259 92. 4.3 Leiomyomas with variant growth patterns (dissecting leiomyoma/intravenous leiomyomatosis) vs Leiomyosarcoma - p. 262 93. 4.4 Epithelioid leiomyoma vs Epithelioid leiomyosarcoma - p. 265 94. 4.5 Cellular leiomyoma vs Endometrial stromal nodule - p. 268 95. 4.6 Endometrial stromal nodule/tumor with irregular margins vs Low-grade endometrial stromal sarcoma - p. 271 96. 4.7 Low-grade endometrial stromal sarcoma with glandular differentiation vs Adenosarcoma - p. 274 97. 4.8 Low-grade endometrial stromal sarcoma with glandular differentiation vs Adenomyosis/endometriosis - p. 277 98. 4.9 Gland-poor adenomyosis vs Low-grade endometrial stromal sarcoma - p. 281 99. 4.10 High- vs Low-grade endometrial stromal sarcoma - p. 284 100. 4.11 Uterine tumor resembling ovarian sex cord tumor (UTROSCT) vs Epithelioid leiomyoma - p. 288 101. 4.12 Perivascular epithelioid cell tumor (PEComa) vs Epithelioid smooth muscle tumor (leiomyoma/leiomyosarcoma) - p. 291 102. 4.13 Lymphangiomyoma/lymphangiomyomatosis vs Leiomyoma - p. 294 103. 4.14 Inflammatory myofibroblastic tumor vs Myxoid leiomyosarcoma - p. 297 104. 4.15 Adenomatoid tumor vs Dilated lymphatics/veins - p. 300 105. 4.16 Adenomatoid tumor vs Lipoleiomyoma - p. 303 106. 4.17 Atypical polypoid adenomyoma vs Invasive FIGO grade 1 endometrioid carcinoma with squamous differentiation - p. 306 107. 4.18 Adenosarcoma vs Adenofibroma - p. 309 108. 4.19 Adenosarcoma vs Benign endometrial polyp - p. 312 109. 4.20 Adenosarcoma with sarcomatous overgrowth vs Malignant mixed müllerian tumor (MMMT; carcinosarcoma) - p. 315 110. 4.21 Uterine artery embolization gelatin microspheres vs Dilated lymphatics/veins - p. 318 111. CHAPTER 5 OVARY - p. 325 112. 5.1 Typical serous borderline tumor (SBT) vs Micropapillary serous borderline tumor (MP-SBT) - p. 327 113. 5.2 Seromucinous borderline tumor (SMBT) vs Low-grade seromucinous carcinoma - p. 330 114. 5.3 Autoimplants of serous borderline tumor (SBT) vs Serous borderline tumor with microinvasion/microinvasive carcinoma - p. 333 115. 5.4 Lymph node “involvement” by serous borderline tumor (SBT) vs Lymph node with endosalpingiosis - p. 336 116. 5.5 Macropapillary pattern of invasive low-grade serous carcinoma (LGSC) vs Serous adenofibroma/cystadenofibroma - p. 339 117. 5.6 High-grade serous carcinoma vs Low-grade serous carcinoma (LGSC) - p. 342 118. 5.7 High-grade serous carcinoma (HGSC) with serous borderline tumor (SBT)–like pattern vs Serous borderline tumor (SBT) - p. 346 119. 5.8 High-grade serous carcinoma vs Carcinosarcoma (malignant müllerian mixed tumor; MMMT) - p. 349 120. 5.9 High-grade serous carcinoma vs High-grade endometrioid carcinoma - p. 352 121. 5.10 Mucinous borderline tumor (MBT) vs MBT with intraepithelial carcinoma - p. 356 122. 5.11 Mucinous borderline tumor (MBT) with microinvasion/microinvasive carcinoma vs MBT with gland rupture - p. 358 123. 5.12 Mucinous borderline tumor (MBT), intestinal type vs Invasive mucinous carcinoma, primary ovarian - p. 361 124. 5.13 Endometrioid borderline tumor (EBT) vs Endometrioid carcinoma, FIGO grade 1 - p. 364 125. 5.14 Endometrioid carcinoma vs Metastatic colonic carcinoma - p. 367 126. 5.15 Endometrioid carcinoma vs Mucinous carcinoma, primary ovarian - p. 370 127. 5.16 Endometrioid carcinoma, sertoliform variant vs Sertoli cell tumor - p. 373 128. 5.17 Endometrioid carcinoma with spindled squamous component vs Carcinosarcoma (MMMT) - p. 376 129. 5.18 Endometrioid carcinoma vs Granulosa cell tumor, adult type - p. 379 130. 5.19 Endometrioid carcinoma with secretory features vs Yolk sac tumor - p. 383 131. 5.20 Clear cell carcinoma vs Yolk sac tumor - p. 387 132. 5.21 Serous borderline tumor (SBT) vs Clear cell carcinoma with papillary pattern - p. 390 133. 5.22 High-grade serous carcinoma (HGSC) with clear cells vs Clear cell carcinoma (CCC) - p. 393 134. 5.23 Adenofibromatous clear cell carcinoma vs Sertoli cell tumor - p. 397 135. 5.24 Benign Brenner tumor vs Borderline Brenner tumor - p. 400 136. 5.25 Borderline Brenner tumor vs Malignant Brenner tumor - p. 403 137. 5.26 Immature teratoma, low-grade vs Mature cystic teratoma with nonimmature neuroepithelial tubules - p. 406 138. 5.27 Malignant sex cord-stromal tumor (adult granulosa cell tumor/poorly differentiated Sertoli-Leydig cell tumor/unclassified sex cord-stromal tumor) vs Cellular fibroma - p. 410 139. 5.28 Adult granulosa cell tumor vs Sertoli-Leydig cell tumor - p. 414 140. 5.29 Luteinized adult granulosa cell tumor vs Thecoma - p. 419 141. 5.30 Adult granulosa cell tumor with pseudopapillary pattern vs High-grade serous carcinoma - p. 422 142. 5.31 Cystic adult granulosa cell tumor vs Follicle cyst - p. 426 143. 5.32 Juvenile granulosa cell tumor (JGCT) vs Small cell carcinoma, hypercalcemic type - p. 429 144. 5.33 Juvenile granulosa cell tumor vs Adult granulosa cell tumor - p. 432 145. 5.34 Pseudoendometrioid well-differentiated Sertoli-Leydig cell tumor vs Endometrioid carcinoma - p. 435 146. 5.35 Sertoli cell tumor vs Carcinoid tumor, primary ovarian - p. 439 147. 5.36 Adult granulosa cell tumor vs Carcinoid tumor, primary ovarian - p. 442 148. 5.37 Sex cord tumor with annular tubules (SCTAT) vs Adult granulosa cell tumor with microfollicular pattern - p. 445 149. 5.38 Steroid (lipid) cell tumor vs Dysgerminoma - p. 448 150. 5.39 Steroid (lipid) cell tumor vs Clear cell carcinoma - p. 451 151. 5.40 Small cell carcinoma, hypercalcemic type vs Lymphoma, diffuse large B-cell, primary ovarian - p. 455 152. 5.41 Metastatic endometrioid adenocarcinoma of endometrial origin vs Endometrioid carcinoma, primary ovarian - p. 458 153. 5.42 Metastatic mucinous carcinoma of colonic origin vs Mucinous carcinoma, primary ovarian - p. 461 154. 5.43 Metastatic endocervical adenocarcinoma, usual type vs Mucinous borderline tumor (MBT) with intraepithelial carcinoma - p. 464 155. 5.44 Metastatic pancreatic adenocarcinoma vs Mucinous borderline tumor (MBT) - p. 467 156. 5.45 Metastatic breast carcinoma vs Endometrioid carcinoma - p. 470 157. 5.46 Metastatic cervical HPV-unrelated adenocarcinoma (adenoma malignum/minimal deviation adenocarcinoma/gastric-type adenocarcinoma) vs Mucinous borderline tumor (MBT) - p. 473 158. 5.47 Secondary ovarian involvement by low-grade mucinous neoplasm of appendix vs Mucinous borderline tumor (MBT) - p. 476 159. 5.48 Endometriotic cyst with epithelial atypia vs Endometriotic cyst with early clear cell carcinoma/intraepithelial clear cell carcinoma - p. 479 160. 5.49 Pregnancy luteoma vs Steroid (lipid) cell tumor - p. 483 161. 5.50 Stromal hyperthecosis vs Metastatic signet ring cell carcinoma - p. 486 162. 5.51 Mesonephric-like carcinoma vs Endometrioid carcinoma - p. 489 163. CHAPTER 6 PERITONEUM/OMENTUM - p. 501 164. 6.1 Noninvasive implants associated with serous borderline tumor vs Endosalpingiosis - p. 502 165. 6.2 Noninvasive implants associated with serous borderline tumor vs Low-grade serous carcinoma (invasive implants) - p. 505 166. 6.3 Nondiagnostic low-grade serous proliferation vs Low-grade serous carcinoma - p. 509 167. 6.4 Well-differentiated papillary mesothelial tumor vs Low-grade serous neoplasms (serous borderline tumor/low-grade serous carcinoma) - p. 514 168. 6.5 High-grade serous carcinoma vs Malignant mesothelioma - p. 518 169. 6.6 Keratin granulomas vs Metastatic endometrioid carcinoma with squamous differentiation - p. 521 170. 6.7 Disseminated peritoneal leiomyomatosis vs Metastatic leiomyosarcoma - p. 524 171. 6.8 Florid mesothelial hyperplasia vs Secondary involvement by ovarian low-grade serous neoplasms (implants of serous borderline tumor/metastatic low-grade serous carcinoma) - p. 527 172. 6.9 Metastatic endometrioid carcinoma vs Endometriosis - p. 531 173. CHAPTER 7 FALLOPIAN TUBE AND PARATUBAL REGION - p. 537 174. 7.1 Papillary tubal hyperplasia vs Normal tubal mucosa - p. 538 175. 7.2 Fallopian tube papilloma vs Well-differentiated tubal neoplasm (FIGO grade 1 endometrioid carcinoma/low-grade serous carcinoma/serous borderline tumor) - p. 541 176. 7.3 Serous tubal intraepithelial carcinoma vs Nondiagnostic mucosal atypia - p. 544 177. 7.4 Serous tubal intraepithelial carcinoma vs Mucosal transitional cell metaplasia - p. 549 178. 7.5 Secretory cell outgrowth (SCOUT) vs Serous tubal intraepithelial carcinoma - p. 552 179. 7.6 Salpingitis isthmica nodosa vs Invasive carcinoma - p. 556 180. 7.7 Detached fragments of endometrial carcinoma within tubal lumen vs FIGO stage III endometrial carcinoma involving fallopian tube - p. 559 181. 7.8 Adenomatoid tumor vs Metastatic nongynecologic carcinoma - p. 562 182. 7.9 Metastatic nongynecologic carcinoma vs Primary tubal carcinoma - p. 565 183. 7.10 Female adnexal tumor of wolffian origin (FATWO) vs Endometrioid carcinoma - p. 569 184. CHAPTER 8 GESTATIONAL TROPHOBLASTIC DISEASE - p. 575 185. 8.1 Nonmolar hydropic abortus vs Partial hydatidiform mole - p. 576 186. 8.2 Partial mole vs Complete mole (including the early variant) - p. 579 187. 8.3 Early complete hydatidiform mole vs Nonmolar hydropic abortus - p. 583 188. 8.4 Complete hydatidiform mole with atypical trophoblastic hyperplasia vs Choriocarcinoma - p. 587 189. 8.5 Mosaic/chimeric conception vs Partial hydatidiform mole - p. 591 190. 8.6 Exaggerated implantation site vs Placental site trophoblastic tumor - p. 595 191. 8.7 Placental site nodule/plaque vs Epithelioid trophoblastic tumor - p. 599 192. 8.8 Placental site trophoblastic tumor vs Epithelioid trophoblastic tumor - p. 603 193. 8.9 Placental site trophoblastic tumor vs Leiomyosarcoma/atypical leiomyoma - p. 606 194. 8.10 Epithelioid trophoblastic tumor vs Squamous cell carcinoma - p. 609 195. 8.11 Choriocarcinoma vs Intermediate trophoblastic tumor - p. 613 196. 8.12 Choriocarcinoma vs Poorly differentiated endometrial carcinoma - p. 616 197. Index - p. 621
No hay muestra disponible
No hay ficha técnica disponible
Offering expert, practical guidance through the decision-making process,Differential Diagnoses in Surgical Pathology: Gynecologic Tract, Second Edition, by Drs. Russell Vang, Anna Yemelyanova, and Jeffrey D. Seidman, helps you systematically solve tough diagnostic challenges in gynecologic pathology and arrive at a correct diagnosis between commonly confused entities. In this fully revised edition, lesions are presented side by side for easy comparison, with clinical and pathological findings in short outline format followed by several full-color images. In addition to illustrating and discussing the classical features of these entities, the authors emphasize atypical features that can complicate diagnoses.
1. Cover - p. Cover 2. Title Page - p. i 3. Copyright - p. iv 4. Preface - p. v 5. Acknowledgments - p. vii 6. Contents - p. ix 7. CHAPTER 1 VULVA AND VAGINA - p. 1 8. 1.1 Vestibular papillomatosis (hymenal tag) vs Condyloma acuminatum - p. 2 9. 1.2 Condyloma acuminatum vs Squamous papilloma - p. 5 10. 1.3 Condyloma acuminatum vs Seborrheic keratosis - p. 8 11. 1.4 Condyloma acuminatum vs Verruca vulgaris (common wart) - p. 11 12. 1.5 Verrucous carcinoma vs Condyloma acuminatum - p. 13 13. 1.6 High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) with condylomatous features vs Condyloma acuminatum - p. 16 14. 1.7 High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) vs Benign squamous epithelium (vulvar skin) - p. 19 15. 1.8 Differentiated-type vulvar intraepithelial neoplasia vs Reactive/reparative atypia - p. 22 16. 1.9 High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) vs Differentiated-type vulvar intraepithelial neoplasia - p. 25 17. 1.10 Basal cell carcinoma vs Basaloid squamous cell carcinoma - p. 28 18. 1.11 Invasive squamous cell carcinoma vs High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) with extension into skin adnexal structures - p. 31 19. 1.12 Invasive squamous cell carcinoma vs High-grade squamous intraepithelial lesion (HSIL, VIN 2-3) with convoluted architecture and/or tangential orientation - p. 34 20. 1.13 Primary extramammary Paget disease vs Pagetoid high-grade squamous intraepithelial lesion (pagetoid HSIL, VIN 2-3) - p. 37 21. 1.14 Melanoma in situ vs Primary extramammary Paget disease - p. 40 22. 1.15 Ectopic prostatic tissue vs Primary vaginal adenocarcinoma - p. 43 23. 1.16 Metastatic adenocarcinoma vs Primary vaginal adenocarcinoma - p. 45 24. 1.17 Prolapsed fallopian tube vs Vaginal adenocarcinoma - p. 48 25. 1.18 Bartholin gland hyperplasia/adenoma vs Primary mucinous carcinoma (Bartholin gland carcinoma) - p. 51 26. 1.19 Hidradenoma papilliferum (papillary hidradenoma) vs Vulvar adenocarcinoma arising from mammary-like glands - p. 53 27. 1.20 Fibroepithelial (mesodermal) stromal polyp vs Aggressive angiomyxoma - p. 56 28. 1.21 Vulvar lymphedema vs Aggressive angiomyxoma - p. 58 29. 1.22 Aggressive angiomyxoma vs Angiomyofibroblastoma - p. 60 30. 1.23 Cellular angiofibroma vs Leiomyoma - p. 62 31. 1.24 Myofibroblastoma vs Leiomyoma - p. 65 32. 1.25 Neurofibroma vs Myofibroblastoma - p. 68 33. 1.26 Spindle cell melanoma vs Leiomyosarcoma - p. 71 34. 1.27 Kaposi sarcoma vs Sarcomatoid (spindled) squamous cell carcinoma - p. 74 35. CHAPTER 2 CERVIX - p. 81 36. 2.1 Low-grade squamous intraepithelial lesion (LSIL) vs Nondiagnostic squamous atypia - p. 82 37. 2.2 Low-grade squamous intraepithelial lesion (LSIL) vs High-grade squamous intraepithelial lesion (HSIL) - p. 85 38. 2.3 Papillary immature squamous metaplasia (immature condyloma) vs Papillary squamous cell carcinoma - p. 88 39. 2.4 High-grade squamous intraepithelial lesion (HSIL) vs Immature squamous metaplasia - p. 91 40. 2.5 High-grade squamous intraepithelial lesion (HSIL) vs Transitional cell metaplasia/atrophy - p. 94 41. 2.6 Attenuated high-grade squamous intraepithelial lesion (HSIL) vs Atypical immature squamous metaplasia - p. 97 42. 2.7 High-grade squamous intraepithelial lesion (HSIL) with extension into endocervical glands vs Superficially invasive squamous cell carcinoma - p. 100 43. 2.8 Adenoid basal epithelioma vs High-grade squamous intraepithelial lesion (HSIL) with extension into endocervical glands - p. 103 44. 2.9 High-grade squamous intraepithelial lesion (HSIL) vs Stratified mucin-producing intraepithelial lesion (SMILE) - p. 106 45. 2.10 Stratified mucin-producing intraepithelial lesion (SMILE) vs Squamous metaplasia with overlying mucinous epithelium - p. 109 46. 2.11 Intraepithelial spread of bladder urothelial carcinoma into the cervix vs High-grade squamous intraepithelial lesion (HSIL) - p. 112 47. 2.12 HPV-related endocervical adenocarcinoma in situ vs Tuboendometrioid metaplasia - p. 115 48. 2.13 Florid adenocarcinoma in situ (AIS, HPV-related) vs HPV-related invasive well-differentiated adenocarcinoma of usual type with AIS-like pattern/Silva pattern A - p. 118 49. 2.14 HPV-related endocervical adenocarcinoma vs Microglandular hyperplasia - p. 121 50. 2.15 HPV-independent endocervical adenocarcinoma (including minimal deviation adenocarcinoma/gastric-type adenocarcinoma) vs Lobular endocervical glandular hyperplasia (LEGH) - p. 124 51. 2.16 HPV-independent endocervical adenocarcinoma (including minimal deviation adenocarcinoma/gastric-type adenocarcinoma) vs HPV-related endocervical adenocarcinoma, mucinous type - p. 127 52. 2.17 Secondary cervical involvement by endometrial carcinoma: cervical stromal invasion vs Confinement to endocervical mucosa - p. 130 53. 2.18 HPV-related invasive endocervical adenocarcinoma of usual type vs Secondary cervical involvement by endometrial endometrioid carcinoma, FIGO grade 1 - p. 132 54. 2.19 Mesonephric hyperplasia (hyperplastic mesonephric duct remnants) vs Secondary involvement of the cervix by endometrial endometrioid adenocarcinoma - p. 135 55. 2.20 Mesonephric hyperplasia (hyperplastic mesonephric duct remnants) vs HPV-related invasive endocervical adenocarcinoma of usual type - p. 138 56. 2.21 Secondary cervical involvement by endometrial endometrioid carcinoma, FIGO grade 3 vs Poorly differentiated cervical squamous cell carcinoma or adenosquamous carcinoma - p. 141 57. 2.22 Placental site nodule/plaque vs Squamous cell carcinoma (well-differentiated, keratinizing) - p. 144 58. 2.23 Squamous cell carcinoma vs Neuroendocrine carcinoma - p. 147 59. 2.24 Embryonal rhabdomyosarcoma, botryoid type vs Inflamed benign endocervical polyp - p. 151 60. 2.25 NTRK-rearranged spindle cell neoplasm/sarcoma vs Inflammatory myofibroblastic tumor - p. 154 61. CHAPTER 3 UTERINE CORPUS (EPITHELIAL LESIONS) - p. 163 62. 3.1 Menstrual endometrium vs Anovulation-related endometrial stromal breakdown/dysfunctional uterine bleeding - p. 164 63. 3.2 Artifactual glandular crowding vs Endometrial hyperplasia - p. 167 64. 3.3 Complex atypical hyperplasia vs Complex hyperplasia without atypia (+/− metaplastic changes) - p. 170 65. 3.4 Endometrial hyperplasia/carcinoma with secretory differentiation vs Secretory endometrium - p. 173 66. 3.5 Endometrial hyperplasia/carcinoma with progestin treatment effect vs Secretory/gestational endometrium - p. 176 67. 3.6 Complex atypical hyperplasia vs FIGO grade 1 endometrioid carcinoma - p. 179 68. 3.7 Fragments of FIGO grade 1 endometrioid carcinoma with metaplastic-like differentiation vs Benign endometrial tissue with metaplastic changes in biopsy/curettage specimens - p. 181 69. 3.8 FIGO grade 1 endometrioid carcinoma with prominent squamous differentiation vs FIGO grade 2 endometrioid carcinoma - p. 184 70. 3.9 Endometrioid carcinoma with papillary architecture vs Serous carcinoma - p. 187 71. 3.10 Endometrioid carcinoma with small nonvillous papillae vs Serous carcinoma - p. 190 72. 3.11 Endometrioid carcinoma vs Serous carcinoma with glandular architecture - p. 193 73. 3.12 Serous intraepithelial carcinoma vs Benign endometrial tissue with reactive/degenerative atypia - p. 197 74. 3.13 High-grade neuroendocrine carcinoma vs Endometrioid carcinoma, FIGO grade 3 - p. 200 75. 3.14 Endometrioid carcinoma with clear cells vs Clear cell carcinoma - p. 203 76. 3.15 Arias-Stella reaction vs Clear cell carcinoma - p. 206 77. 3.16 Corded and hyalinized pattern of endometrioid carcinoma vs Malignant mixed müllerian tumor (MMMT; carcinosarcoma) - p. 209 78. 3.17 High-grade endometrial carcinoma (FIGO grade 3 endometrioid carcinoma/serous carcinoma) vs Malignant mixed müllerian tumor (MMMT; carcinosarcoma) - p. 213 79. 3.18 Dedifferentiated carcinoma vs High-grade endometrial carcinoma (malignant mixed müllerian tumor [MMMT; carcinosarcoma]/FIGO grade 3 endometrioid carcinoma) - p. 216 80. 3.19 Mesonephric/mesonephric-like adenocarcinoma vs Endometrioid carcinoma - p. 220 81. 3.20 Endometrial carcinoma involving irregular endometrial-myometrial junction vs Endometrial carcinoma with superficial myoinvasion - p. 223 82. 3.21 Endometrial carcinoma with involvement of adenomyosis vs Endometrial carcinoma with myoinvasion - p. 226 83. 3.22 Endometrial carcinoma with vascular pseudoinvasion vs Endometrial carcinoma with true lymph-vascular space invasion (LVSI) - p. 229 84. 3.23 Minute and detached fragments of ovarian/tubal high-grade serous carcinoma in uterine biopsy/curettage vs Primary endometrial serous carcinoma - p. 233 85. 3.24 Metastatic nongynecologic carcinoma with glandular pattern involving endometrium vs Endometrial endometrioid carcinoma - p. 236 86. 3.25 Secondary uterine corpus involvement by cervical poorly differentiated squamous cell carcinoma vs Primary endometrial FIGO grade 3 endometrioid carcinoma - p. 239 87. 3.26 Endometrial biopsy/curettage: secondary endometrial involvement by endocervical well-differentiated adenocarcinoma of usual type vs Primary endometrial FIGO grade 1 endometrioid carcinoma - p. 242 88. 3.27 Endocervical microglandular hyperplasia (MGH) vs Microglandular hyperplasia (MGH)-like endometrial carcinoma in biopsy/curettage specimens - p. 246 89. CHAPTER 4 UTERINE CORPUS (PURE MESENCHYMAL AND MIXED EPITHELIAL-MESENCHYMAL LESIONS) - p. 255 90. 4.1 Atypical leiomyoma vs Leiomyosarcoma - p. 256 91. 4.2 Infarcted cellular leiomyoma vs Smooth muscle tumor of uncertain malignant potential (STUMP) - p. 259 92. 4.3 Leiomyomas with variant growth patterns (dissecting leiomyoma/intravenous leiomyomatosis) vs Leiomyosarcoma - p. 262 93. 4.4 Epithelioid leiomyoma vs Epithelioid leiomyosarcoma - p. 265 94. 4.5 Cellular leiomyoma vs Endometrial stromal nodule - p. 268 95. 4.6 Endometrial stromal nodule/tumor with irregular margins vs Low-grade endometrial stromal sarcoma - p. 271 96. 4.7 Low-grade endometrial stromal sarcoma with glandular differentiation vs Adenosarcoma - p. 274 97. 4.8 Low-grade endometrial stromal sarcoma with glandular differentiation vs Adenomyosis/endometriosis - p. 277 98. 4.9 Gland-poor adenomyosis vs Low-grade endometrial stromal sarcoma - p. 281 99. 4.10 High- vs Low-grade endometrial stromal sarcoma - p. 284 100. 4.11 Uterine tumor resembling ovarian sex cord tumor (UTROSCT) vs Epithelioid leiomyoma - p. 288 101. 4.12 Perivascular epithelioid cell tumor (PEComa) vs Epithelioid smooth muscle tumor (leiomyoma/leiomyosarcoma) - p. 291 102. 4.13 Lymphangiomyoma/lymphangiomyomatosis vs Leiomyoma - p. 294 103. 4.14 Inflammatory myofibroblastic tumor vs Myxoid leiomyosarcoma - p. 297 104. 4.15 Adenomatoid tumor vs Dilated lymphatics/veins - p. 300 105. 4.16 Adenomatoid tumor vs Lipoleiomyoma - p. 303 106. 4.17 Atypical polypoid adenomyoma vs Invasive FIGO grade 1 endometrioid carcinoma with squamous differentiation - p. 306 107. 4.18 Adenosarcoma vs Adenofibroma - p. 309 108. 4.19 Adenosarcoma vs Benign endometrial polyp - p. 312 109. 4.20 Adenosarcoma with sarcomatous overgrowth vs Malignant mixed müllerian tumor (MMMT; carcinosarcoma) - p. 315 110. 4.21 Uterine artery embolization gelatin microspheres vs Dilated lymphatics/veins - p. 318 111. CHAPTER 5 OVARY - p. 325 112. 5.1 Typical serous borderline tumor (SBT) vs Micropapillary serous borderline tumor (MP-SBT) - p. 327 113. 5.2 Seromucinous borderline tumor (SMBT) vs Low-grade seromucinous carcinoma - p. 330 114. 5.3 Autoimplants of serous borderline tumor (SBT) vs Serous borderline tumor with microinvasion/microinvasive carcinoma - p. 333 115. 5.4 Lymph node “involvement” by serous borderline tumor (SBT) vs Lymph node with endosalpingiosis - p. 336 116. 5.5 Macropapillary pattern of invasive low-grade serous carcinoma (LGSC) vs Serous adenofibroma/cystadenofibroma - p. 339 117. 5.6 High-grade serous carcinoma vs Low-grade serous carcinoma (LGSC) - p. 342 118. 5.7 High-grade serous carcinoma (HGSC) with serous borderline tumor (SBT)–like pattern vs Serous borderline tumor (SBT) - p. 346 119. 5.8 High-grade serous carcinoma vs Carcinosarcoma (malignant müllerian mixed tumor; MMMT) - p. 349 120. 5.9 High-grade serous carcinoma vs High-grade endometrioid carcinoma - p. 352 121. 5.10 Mucinous borderline tumor (MBT) vs MBT with intraepithelial carcinoma - p. 356 122. 5.11 Mucinous borderline tumor (MBT) with microinvasion/microinvasive carcinoma vs MBT with gland rupture - p. 358 123. 5.12 Mucinous borderline tumor (MBT), intestinal type vs Invasive mucinous carcinoma, primary ovarian - p. 361 124. 5.13 Endometrioid borderline tumor (EBT) vs Endometrioid carcinoma, FIGO grade 1 - p. 364 125. 5.14 Endometrioid carcinoma vs Metastatic colonic carcinoma - p. 367 126. 5.15 Endometrioid carcinoma vs Mucinous carcinoma, primary ovarian - p. 370 127. 5.16 Endometrioid carcinoma, sertoliform variant vs Sertoli cell tumor - p. 373 128. 5.17 Endometrioid carcinoma with spindled squamous component vs Carcinosarcoma (MMMT) - p. 376 129. 5.18 Endometrioid carcinoma vs Granulosa cell tumor, adult type - p. 379 130. 5.19 Endometrioid carcinoma with secretory features vs Yolk sac tumor - p. 383 131. 5.20 Clear cell carcinoma vs Yolk sac tumor - p. 387 132. 5.21 Serous borderline tumor (SBT) vs Clear cell carcinoma with papillary pattern - p. 390 133. 5.22 High-grade serous carcinoma (HGSC) with clear cells vs Clear cell carcinoma (CCC) - p. 393 134. 5.23 Adenofibromatous clear cell carcinoma vs Sertoli cell tumor - p. 397 135. 5.24 Benign Brenner tumor vs Borderline Brenner tumor - p. 400 136. 5.25 Borderline Brenner tumor vs Malignant Brenner tumor - p. 403 137. 5.26 Immature teratoma, low-grade vs Mature cystic teratoma with nonimmature neuroepithelial tubules - p. 406 138. 5.27 Malignant sex cord-stromal tumor (adult granulosa cell tumor/poorly differentiated Sertoli-Leydig cell tumor/unclassified sex cord-stromal tumor) vs Cellular fibroma - p. 410 139. 5.28 Adult granulosa cell tumor vs Sertoli-Leydig cell tumor - p. 414 140. 5.29 Luteinized adult granulosa cell tumor vs Thecoma - p. 419 141. 5.30 Adult granulosa cell tumor with pseudopapillary pattern vs High-grade serous carcinoma - p. 422 142. 5.31 Cystic adult granulosa cell tumor vs Follicle cyst - p. 426 143. 5.32 Juvenile granulosa cell tumor (JGCT) vs Small cell carcinoma, hypercalcemic type - p. 429 144. 5.33 Juvenile granulosa cell tumor vs Adult granulosa cell tumor - p. 432 145. 5.34 Pseudoendometrioid well-differentiated Sertoli-Leydig cell tumor vs Endometrioid carcinoma - p. 435 146. 5.35 Sertoli cell tumor vs Carcinoid tumor, primary ovarian - p. 439 147. 5.36 Adult granulosa cell tumor vs Carcinoid tumor, primary ovarian - p. 442 148. 5.37 Sex cord tumor with annular tubules (SCTAT) vs Adult granulosa cell tumor with microfollicular pattern - p. 445 149. 5.38 Steroid (lipid) cell tumor vs Dysgerminoma - p. 448 150. 5.39 Steroid (lipid) cell tumor vs Clear cell carcinoma - p. 451 151. 5.40 Small cell carcinoma, hypercalcemic type vs Lymphoma, diffuse large B-cell, primary ovarian - p. 455 152. 5.41 Metastatic endometrioid adenocarcinoma of endometrial origin vs Endometrioid carcinoma, primary ovarian - p. 458 153. 5.42 Metastatic mucinous carcinoma of colonic origin vs Mucinous carcinoma, primary ovarian - p. 461 154. 5.43 Metastatic endocervical adenocarcinoma, usual type vs Mucinous borderline tumor (MBT) with intraepithelial carcinoma - p. 464 155. 5.44 Metastatic pancreatic adenocarcinoma vs Mucinous borderline tumor (MBT) - p. 467 156. 5.45 Metastatic breast carcinoma vs Endometrioid carcinoma - p. 470 157. 5.46 Metastatic cervical HPV-unrelated adenocarcinoma (adenoma malignum/minimal deviation adenocarcinoma/gastric-type adenocarcinoma) vs Mucinous borderline tumor (MBT) - p. 473 158. 5.47 Secondary ovarian involvement by low-grade mucinous neoplasm of appendix vs Mucinous borderline tumor (MBT) - p. 476 159. 5.48 Endometriotic cyst with epithelial atypia vs Endometriotic cyst with early clear cell carcinoma/intraepithelial clear cell carcinoma - p. 479 160. 5.49 Pregnancy luteoma vs Steroid (lipid) cell tumor - p. 483 161. 5.50 Stromal hyperthecosis vs Metastatic signet ring cell carcinoma - p. 486 162. 5.51 Mesonephric-like carcinoma vs Endometrioid carcinoma - p. 489 163. CHAPTER 6 PERITONEUM/OMENTUM - p. 501 164. 6.1 Noninvasive implants associated with serous borderline tumor vs Endosalpingiosis - p. 502 165. 6.2 Noninvasive implants associated with serous borderline tumor vs Low-grade serous carcinoma (invasive implants) - p. 505 166. 6.3 Nondiagnostic low-grade serous proliferation vs Low-grade serous carcinoma - p. 509 167. 6.4 Well-differentiated papillary mesothelial tumor vs Low-grade serous neoplasms (serous borderline tumor/low-grade serous carcinoma) - p. 514 168. 6.5 High-grade serous carcinoma vs Malignant mesothelioma - p. 518 169. 6.6 Keratin granulomas vs Metastatic endometrioid carcinoma with squamous differentiation - p. 521 170. 6.7 Disseminated peritoneal leiomyomatosis vs Metastatic leiomyosarcoma - p. 524 171. 6.8 Florid mesothelial hyperplasia vs Secondary involvement by ovarian low-grade serous neoplasms (implants of serous borderline tumor/metastatic low-grade serous carcinoma) - p. 527 172. 6.9 Metastatic endometrioid carcinoma vs Endometriosis - p. 531 173. CHAPTER 7 FALLOPIAN TUBE AND PARATUBAL REGION - p. 537 174. 7.1 Papillary tubal hyperplasia vs Normal tubal mucosa - p. 538 175. 7.2 Fallopian tube papilloma vs Well-differentiated tubal neoplasm (FIGO grade 1 endometrioid carcinoma/low-grade serous carcinoma/serous borderline tumor) - p. 541 176. 7.3 Serous tubal intraepithelial carcinoma vs Nondiagnostic mucosal atypia - p. 544 177. 7.4 Serous tubal intraepithelial carcinoma vs Mucosal transitional cell metaplasia - p. 549 178. 7.5 Secretory cell outgrowth (SCOUT) vs Serous tubal intraepithelial carcinoma - p. 552 179. 7.6 Salpingitis isthmica nodosa vs Invasive carcinoma - p. 556 180. 7.7 Detached fragments of endometrial carcinoma within tubal lumen vs FIGO stage III endometrial carcinoma involving fallopian tube - p. 559 181. 7.8 Adenomatoid tumor vs Metastatic nongynecologic carcinoma - p. 562 182. 7.9 Metastatic nongynecologic carcinoma vs Primary tubal carcinoma - p. 565 183. 7.10 Female adnexal tumor of wolffian origin (FATWO) vs Endometrioid carcinoma - p. 569 184. CHAPTER 8 GESTATIONAL TROPHOBLASTIC DISEASE - p. 575 185. 8.1 Nonmolar hydropic abortus vs Partial hydatidiform mole - p. 576 186. 8.2 Partial mole vs Complete mole (including the early variant) - p. 579 187. 8.3 Early complete hydatidiform mole vs Nonmolar hydropic abortus - p. 583 188. 8.4 Complete hydatidiform mole with atypical trophoblastic hyperplasia vs Choriocarcinoma - p. 587 189. 8.5 Mosaic/chimeric conception vs Partial hydatidiform mole - p. 591 190. 8.6 Exaggerated implantation site vs Placental site trophoblastic tumor - p. 595 191. 8.7 Placental site nodule/plaque vs Epithelioid trophoblastic tumor - p. 599 192. 8.8 Placental site trophoblastic tumor vs Epithelioid trophoblastic tumor - p. 603 193. 8.9 Placental site trophoblastic tumor vs Leiomyosarcoma/atypical leiomyoma - p. 606 194. 8.10 Epithelioid trophoblastic tumor vs Squamous cell carcinoma - p. 609 195. 8.11 Choriocarcinoma vs Intermediate trophoblastic tumor - p. 613 196. 8.12 Choriocarcinoma vs Poorly differentiated endometrial carcinoma - p. 616 197. Index - p. 621
No hay muestra disponible
No hay ficha técnica disponible
